Welcome to our dedicated page for OCULAR THERAPEUTIX SEC filings (Ticker: OCUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on OCULAR THERAPEUTIX's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into OCULAR THERAPEUTIX's regulatory disclosures and financial reporting.
Ocular Therapeutix Chief Strategy Officer Sanjay Nayak reported an automatic sale of 1,759 shares of common stock. The shares were sold in an open-market transaction at a weighted average price of $8.28 per share under a pre-arranged durable automatic sale instruction.
The sale was made to cover tax withholding obligations tied to the vesting of restricted stock units on February 22, 2026, and is described as non-discretionary. After this sell-to-cover transaction, Nayak directly held 330,653 shares of Ocular Therapeutix common stock.
Ocular Therapeutix, Inc.’s Chief Medical Officer, Nadia Waheed, reported an open‑market sale of 3,510 shares of common stock at a weighted average price of $7.74 per share on February 20, 2026. The sale was executed under a durable automatic sale instruction adopted on June 1, 2024 to cover tax withholding from restricted stock units that vested on February 11, 2026, and is described as non‑discretionary. Following this transaction, Waheed beneficially owns 314,907 shares of Ocular Therapeutix common stock.
Ocular Therapeutix director Richard L. Lindstrom, MD, bought shares of the company’s common stock in the open market. On this transaction date, he purchased 60,229 shares at a weighted average price of $7.66 per share, bringing his directly held stake to 246,933 shares.
OCUL submitted a notice to sell 2,810 shares of common stock tied to restricted stock vesting under a registered plan, dated 02/22/2026.
Shares outstanding were 217,691,779 as of 02/23/2026. The excerpt also shows a prior sale of 3,007 common shares on 11/24/2025 for $36,150.15.
Oculus Therapeutics (OCUL) reported proposed sales of common stock via a Form 144 notice tied to restricted shares vesting under a registered plan on 02/22/2026.
The filing names Pravin Dugel and lists prior sales of 124,882 shares on 02/12/2026 for $1,128,583.61 and 19,530 shares on 11/24/2025 for $235,082.61.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a notice regarding the proposed sale of 3,057 common shares tied to restricted stock vesting under a registered plan, dated 02/22/2026. The filing lists that the sale method is by the Issuer.
The excerpt also shows a prior sale by Jeffrey S. Heier of 3,469 common shares on 11/24/2025, with a numeric value 41,771.96 recorded alongside that transaction.
OCUL notice of a proposed sale of 1,759 common shares tied to restricted stock vesting under a registered plan on 02/22/2026.
The filing also records prior sales by Sanjay Nayak of 10,348 shares on 02/12/2026 and 1,878 shares on 11/24/2025.
Nadia K. Waheed submitted a Form 144 reporting a proposed sale of 3,510 shares of common stock tied to restricted stock vesting under a registered plan, dated 02/11/2026. The filing also shows 7,863 shares were sold on 02/12/2026.
Ocular Therapeutix Chief Operating Officer Donald Notman reported an automatic open-market sale of 11,446 shares of common stock at a weighted average price of $9.04 per share on February 12, 2026. The sale was executed under a durable automatic sale instruction to satisfy tax withholding obligations tied to restricted stock units that vested on February 11, 2026, and was not a discretionary trade. Following this transaction, Notman directly owns 366,356 shares of Ocular Therapeutix common stock.
Ocular Therapeutix Chief Strategy Officer Sanjay Nayak executed an automatic sale of 10,348 shares of common stock on February 12, 2026 at a weighted average price of $9.04 per share. The transaction was carried out under a durable automatic sale instruction to cover tax withholding obligations tied to restricted stock units that vested on February 11, 2026, and was not a discretionary trade. After this sell-to-cover transaction, Nayak directly held 332,412 shares of Ocular Therapeutix common stock.